```html

Supraventricular Tachycardia (SVT) – A Complete Medical Guide

Overview

Supraventricular tachycardia (SVT) is an umbrella term for a group of abnormal heart rhythms that originate above the heart’s ventricles – in the atria or the atrioventricular (AV) node. These rhythms cause the heart to beat faster than normal, often in sudden bursts that can last seconds to hours.

• Typical heart rate: 150–250 beats per minute (bpm) versus a normal resting rate of 60–100 bpm.
• Prevalence: SVT affects roughly 2–3 persons per 1,000 in the general population; up to 0.5 % of newborns have SVT, and 1 % of adults will experience an episode at some point in life.<sup>[1][2]</sup>
• Who it affects: It can occur at any age, but:
  • Infants and children often have congenital accessory pathways.
  • Young adults (20‑40 y) are the most commonly diagnosed group.
  • Women are slightly more likely than men to develop SVT (≈55 % of cases).<sup>[3]</sup>

Symptoms

SVT episodes can be brief and unnoticed, or they can cause distressing sensations. Symptoms vary with the speed of the heart rate, the duration of the episode, and the individual’s baseline health.

Common signs

• Pounding or fluttering in the chest: often described as “the heart is racing.”
• Dizziness or light‑headedness: caused by reduced cardiac output.
• Shortness of breath: especially during an episode, even at rest.
• Palpitations: an awareness of rapid, irregular beats.
• Chest discomfort: tightness or mild pain, usually non‑ischemic.
• Fatigue or weakness: after an episode due to temporary low perfusion.

Less common but important symptoms

• Cold sweat
• Feeling “blurred” or unable to concentrate
• Syncope (fainting) – rare, suggests a more severe arrhythmia or underlying heart disease
• Vomiting or nausea – especially in children

Causes and Risk Factors

SVT is usually the result of a problem in the heart’s electrical conduction system. The most frequent mechanisms include:

Re‑entrant pathways

• Atrioventricular Nodal Re‑entrant Tachycardia (AVNRT): a loop within or near the AV node.
• Atrioventricular Re‑entrant Tachycardia (AVRT): an accessory pathway (e.g., Wolff‑Parkinson‑White syndrome) that bypasses the AV node.

Triggered activity

• Abnormal automaticity in atrial tissue (e.g., atrial premature beats) that initiates a rapid rhythm.

Risk factors

• Age: infants and young adults are most vulnerable.
• Congenital heart defects or structural abnormalities.
• Family history: genetic predisposition to accessory pathways.
• Certain medications: stimulants (e.g., caffeine, nicotine, decongestants), some asthma drugs, and illicit stimulants.
• Electrolyte disturbances: low potassium or magnesium.
• Thyroid disease: hyperthyroidism can precipitate SVT.
• Alcohol or drug use: binge drinking, cocaine, or methamphetamine.
• Stress and lack of sleep: sympathetic nervous system activation.

Diagnosis

Because SVT can be intermittent, the diagnostic approach often combines a detailed history with targeted testing.

Clinical evaluation

• History of episode frequency, duration, triggers, and associated symptoms.
• Physical exam – rapid pulse, possible BP drop during an episode.

Electrocardiogram (ECG)

• Resting 12‑lead ECG: May be normal between episodes. However, characteristic findings (e.g., delta wave in WPW) can be present.
• Event monitor or Holter monitor: 24‑48 h (Holter) or up to 30 days (event recorder) to capture transient episodes.

Electrophysiology (EP) Study

Invasive test performed in a cardiac electrophysiology lab. Small catheters map the heart’s electrical pathways, pinpointing the exact circuit responsible for SVT. It is both diagnostic and therapeutic (allows immediate ablation).

Other supportive tests

• Blood tests: electrolytes, thyroid function, drug screen if indicated.
• Echocardiogram: rules out structural heart disease that could modify management.

Treatment Options

Treatment is tailored to episode severity, frequency, patient preference, and underlying heart health.

Acute (on‑the‑spot) management

1. Vagal maneuvers – first‑line, non‑pharmacologic techniques:
   • Valsalva maneuver (bearing down as if having a bowel movement).
   • Cold water facial immersion (diving reflex).
   • Carotid sinus massage – only by trained professionals.
   Successful in 20‑30 % of SVT episodes.<sup>[4]</sup>
2. Medication:
   • Intravenous adenosine – rapid, short‑acting blocker of AV‑node conduction; termination in 60‑90 % of AVNRT/AVRT.
   • Intravenous calcium channel blockers (verapamil, diltiazem) or beta‑blockers (esmolol) if adenosine contraindicated.
3. Cardioversion: Synchronized electrical shock, reserved for hemodynamically unstable patients (e.g., hypotension, chest pain, syncope).

Long‑term (preventive) therapy

• Medications:
  • Beta‑blockers (metoprolol, atenolol) – reduce AV‑node conduction.
  • Calcium‑channel blockers (verapamil, diltiazem) – especially for patients intolerant of beta‑blockers.
  • Anti‑arrhythmic agents (flecainide, propafenone, sotalol) – used when first‑line drugs are ineffective.
• Catheter ablation: Radiofrequency or cryoablation destroys the abnormal pathway. Success rates 95‑98 % for AVNRT and 85‑95 % for AVRT, with low recurrence.<sup>[5]</sup> Often considered after:
  • ≥2 symptomatic episodes per month,
  • medication side‑effects, or
  • patient preference for a “cure.”
• Lifestyle modifications: Limit caffeine, alcohol, and stimulants; maintain adequate sleep; manage stress.

Living with Supraventricular Tachycardia (SVT)

Most people with SVT lead normal lives. The key is to understand your triggers, keep a symptom diary, and stay in communication with your healthcare team.

Practical daily‑management tips

• Keep a log: Note date, time, heart rate (if you have a monitor), possible triggers, and how long the episode lasted.
• Know your vagal maneuvers: Practice the Valsalva technique at home so you can use it quickly.
• Medication adherence: Take prescribed drugs exactly as directed; never stop abruptly without talking to your doctor.
• Wearable heart‑rate monitor: A smartwatch with ECG capability can help capture events.
• Exercise safely: Most patients can exercise; start with low‑intensity activity and increase gradually under physician guidance.
• Stress‑reduction strategies: Yoga, meditation, deep‑breathing exercises, or counseling.
• Stay hydrated & balanced electrolytes: Particularly if you sweat heavily during exercise.

Prevention

While you cannot change genetics, several modifiable factors can lower the likelihood of an SVT episode.

• Limit caffeine to < 200 mg per day (≈1 cup coffee).
• Avoid nicotine and illicit stimulants.
• Moderate alcohol intake (≤ 1 drink/day for women, ≤ 2 drinks/day for men).
• Maintain a healthy weight – obesity can increase sympathetic tone.
• Manage thyroid disease promptly.
• Correct electrolyte abnormalities; consider a potassium‑rich diet if you’re on diuretics.
• Ensure adequate sleep (7‑9 hours) and practice good sleep hygiene.

Complications

Although SVT is often benign, untreated or recurrent episodes can lead to serious problems:

• Heart failure: Persistent tachycardia can weaken the heart muscle (tachy‑cardiomyopathy).
• Syncope or injury: Sudden loss of consciousness can cause falls.
• Ischemic chest pain: Rapid rates increase myocardial oxygen demand; rare in healthy hearts but possible in those with coronary disease.
• Psychological impact: Anxiety or panic disorder may develop from fear of episodes.

When to Seek Emergency Care

References

1. Mayo Clinic. “Supraventricular tachycardia (SVT).” Updated 2023. https://www.mayoclinic.org/diseases-conditions/svt
2. American Heart Association. “Prevalence of SVT.” 2022. https://www.heart.org
3. Cleveland Clinic. “Who gets SVT?” 2021. https://my.clevelandclinic.org
4. J Am Coll Cardiol. “Effectiveness of Vagal Maneuvers in SVT.” 2020;75(12):1542‑1549.
5. Heart Rhythm Society. “Guidelines for Catheter Ablation of SVT.” 2023. https://www.hrsonline.org

```